Drug Details

Efzofitimod is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of histidyl-tRNA synthetase (HARS). Efzofitimod selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. NRP2 is a new immune target in ILD that is upstream of other therapeutic targets, which allows it to hit multiple inflammatory and pro-fibrotic pathways, addressing the complex immune pathology observed in ILD.

Study Purpose

This is a 2-part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD.

Find a Clinical Trial